Sequoia Financial Advisors LLC Boosts Holdings in Cencora, Inc. $COR

Sequoia Financial Advisors LLC lifted its holdings in Cencora, Inc. (NYSE:COR) by 25.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 12,428 shares of the company’s stock after acquiring an additional 2,530 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Cencora were worth $4,197,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. United Bank lifted its stake in Cencora by 4.5% in the second quarter. United Bank now owns 7,032 shares of the company’s stock worth $2,109,000 after purchasing an additional 305 shares during the last quarter. Nebula Research & Development LLC bought a new position in shares of Cencora during the second quarter valued at about $595,000. Treasurer of the State of North Carolina grew its stake in shares of Cencora by 7.9% during the second quarter. Treasurer of the State of North Carolina now owns 85,534 shares of the company’s stock valued at $25,647,000 after buying an additional 6,244 shares during the last quarter. Diversify Advisory Services LLC increased its holdings in shares of Cencora by 94.1% in the second quarter. Diversify Advisory Services LLC now owns 2,585 shares of the company’s stock worth $747,000 after buying an additional 1,253 shares during the period. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in shares of Cencora by 26.0% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 73,452 shares of the company’s stock worth $22,025,000 after buying an additional 15,154 shares during the period. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora News Summary

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Cencora raised FY2026 EPS guidance to $17.65-$17.90 and resumed a $1 billion share repurchase program, signaling management confidence in earnings power and capital returns.
• Positive Sentiment: Several Wall Street firms still maintained bullish ratings after cutting price targets, including Citi and Baird, suggesting analysts continue to see upside despite the selloff.
• Neutral Sentiment: Commentary around the stock emphasizes a “valuation debate” and whether the post-earnings decline was overdone, indicating investors are reassessing expectations rather than reacting to a new operational shock. Cencora NYSE Composite Reset Sparks Valuation Debate
• Neutral Sentiment: Analyst and media coverage is also centered on margin expansion versus growth, reflecting debate over whether Cencora is prioritizing profitability and buybacks over top-line momentum. Is Cencora (COR) Prioritizing Margin Expansion Over Growth With Its Raised EPS Outlook and Buybacks?
• Negative Sentiment: The main bearish driver is the earnings report, which missed EPS estimates and came with sales below analyst expectations, raising concerns about near-term growth momentum. Cencora (NYSE:COR) reports sales below analyst estimates in Q1 CY2026 earnings
• Negative Sentiment: A securities fraud investigation announcement could add overhang and legal-risk concerns, potentially worsening sentiment until more details are known. Securities Fraud Investigation Into Cencora, Inc. (COR) Announced

Cencora Stock Up 2.2%

Shares of NYSE:COR opened at $261.16 on Friday. The stock’s 50-day moving average is $327.81 and its 200 day moving average is $342.26. The company has a market cap of $50.80 billion, a PE ratio of 20.03, a P/E/G ratio of 1.21 and a beta of 0.64. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.51. Cencora, Inc. has a 1 year low of $244.82 and a 1 year high of $377.54.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). The business had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.The company’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same quarter last year, the business posted $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Sell-side analysts anticipate that Cencora, Inc. will post 17.73 EPS for the current year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 1st. Investors of record on Friday, May 15th will be issued a $0.60 dividend. The ex-dividend date is Friday, May 15th. This represents a $2.40 annualized dividend and a yield of 0.9%. Cencora’s payout ratio is 18.40%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. William Blair started coverage on Cencora in a report on Tuesday, April 28th. They set a “market perform” rating for the company. Barclays lifted their price target on Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a research note on Friday, February 13th. UBS Group boosted their price objective on Cencora from $410.00 to $412.00 and gave the company a “buy” rating in a research report on Thursday. Robert W. Baird cut their target price on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a report on Thursday. Finally, Leerink Partners reaffirmed an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. Twelve investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and a consensus target price of $388.42.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.